Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus
Marc Evans, Angharad R. Morgan, Sarah Davies, et al.
Age and Ageing (2022) Vol. 51, Iss. 10
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis
Rami Aldafas, Thomas Crabtree, Mohammed Alkharaiji, et al.
Age and Ageing (2024) Vol. 53, Iss. 1
Open Access | Times Cited: 15
Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults
Ashkan Hashemi, Min Ji Kwak, Parag Goyal
Drugs & Aging (2025)
Closed Access | Times Cited: 1
Hypertensive heart disease in older patients: considerations for clinical practice
Miguel Camafort, Alexandros Kasiakogias, Enrico Agabiti‐Rosei, et al.
European Journal of Internal Medicine (2025)
Open Access | Times Cited: 1
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Cardiovascular aging: from cellular and molecular changes to therapeutic interventions
Angeliki Vakka, Junco S. Warren, Konstantinos Drosatos
The Journal of Cardiovascular Aging (2023)
Open Access | Times Cited: 20
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Samuel Seidu, Vicki Alabraba, Sarah Davies, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1099-1124
Open Access | Times Cited: 8
A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review PART II—Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory
Marcin Piechocki, Tadeusz Przewłocki, Piotr Pieniążek, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1508-1508
Open Access | Times Cited: 7
Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review
Eveline P. van Poelgeest, M. Louis Handoko, Majon Muller, et al.
European Geriatric Medicine (2023) Vol. 14, Iss. 4, pp. 659-674
Open Access | Times Cited: 15
Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
Minji Sohn, Johannes W. Dietrich, Michael A. Nauck, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 13
The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
Alan J. Sinclair, Ahmed H. Abdelhafiz
Metabolites (2025) Vol. 15, Iss. 1, pp. 49-49
Open Access
Safety and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Older Adults with Variable Disease States: A Meta-analysis of Large Placebo-Controlled Trials
Syeda Ayesha Shah, Hasan Mushahid, Ali Salman, et al.
Drugs & Aging (2025)
Closed Access
Impact of sodium-glucose cotransporter-2 inhibitors on aging biomarkers and plasma ceramide levels in type 2 diabetes: beyond glycemic control
Youssef M. Shalaby, Mohammed M. Nakhal, Bachar Afandi, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access
The Safety and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Sarcopenia or Frailty: Double Edged Sword?
Ayami Naito, Yuji Nagatomo, Akane Kawai, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 2, pp. 141-141
Open Access | Times Cited: 3
Key results from observational studies and real‐world evidence of sodium‐glucose cotransporter‐2 inhibitor effectiveness and safety in reducing cardio‐renal risk
Thomas Nyström
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 2
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Ja Young Jeon, Dae Jung Kim
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 5, pp. 837-846
Closed Access | Times Cited: 2
Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety
Amr Elkammash, Simpson Shiu Chung Tam, Geethana Yogarajah, et al.
Cureus (2023)
Open Access | Times Cited: 5
Management of type 2 diabetes in patients with frailty
Kara Hawker, Ripa Akter, Frank Molnar, et al.
Canadian Family Physician (2024) Vol. 70, Iss. 1, pp. 30-32
Open Access | Times Cited: 1
Response to letter by Masse O et al. STOPP/START version 3: clinical pharmacists are raising alarms
Denis O’Mahony, Antonio Cherubini, Anna Renom‐Guiteras, et al.
European Geriatric Medicine (2024) Vol. 15, Iss. 2, pp. 593-596
Closed Access | Times Cited: 1
STOPP/START version 3: clinical pharmacists are raising concerns
Olivier Massé, Joëlle Flamand Villeneuve, Alexandre Lahaie, et al.
European Geriatric Medicine (2024) Vol. 15, Iss. 2, pp. 589-591
Closed Access | Times Cited: 1
Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, et al.
ESC Heart Failure (2024)
Open Access | Times Cited: 1
Investigating the place of sodium-glucose cotransporter-2 inhibitors and dual sodium-glucose cotransporter-1 and dual sodium-glucose cotransporter-2 inhibitors in heart failure therapy: a systematic review of the literature
Taylor McKenzie, Genevieve M Hale, Amelia Miner, et al.
Heart Failure Reviews (2024) Vol. 29, Iss. 2, pp. 549-558
Closed Access | Times Cited: 1
Incorporating Prognosis into Clinical Decision-Making for Older Adults with Diabetes
William James Deardorff, Kenneth E. Covinsky
Journal of General Internal Medicine (2023) Vol. 38, Iss. 13, pp. 2857-2859
Open Access | Times Cited: 2
Prise en charge du diabète de type 2 chez les patients fragiles
Kara Hawker, Ripa Akter, Frank Molnar, et al.
Canadian Family Physician (2024) Vol. 70, Iss. 1, pp. e10-e13
Open Access
Meta-analysis of the efficacy and impact on cardiac function of sodium–glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients
Weidong Li, Xuanyang Shen, Meiqi Zhang, et al.
Medicine (2024) Vol. 103, Iss. 45, pp. e40409-e40409
Open Access
Assessment of the Utilization of Sodium–Glucose Cotransporter-2 Inhibitors in Patients Without Diabetes
Takuma Koinuma, Minoru Yoshida, Manabu Akazawa
Pharmacoepidemiology (2024) Vol. 3, Iss. 4, pp. 383-393
Open Access
Page 1 - Next Page

Scroll to top